IMR Press / FBL / Volume 20 / Issue 3 / DOI: 10.2741/4322

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Dehydroxymethylepoxyquinomicin selectively ablates T-CAEBV cells
Show Less
1 Department of Pediatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (SJTU-SM), 1665 Kongjiang Road, Shanghai 200092, China
2 State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (SJTU-SM), 197 Ruijin Road II, Shanghai 200025, China
3 Department of Pediatrics, The First Affiliated Hospital of Guangzhou Medical University, 151 West Yanjiang Rd, Guangzhou, 510120, China
Academic Editor:Fei He
Front. Biosci. (Landmark Ed) 2015, 20(3), 502–514;
Published: 1 January 2015
(This article belongs to the Special Issue Cellular immunology and stem cell biology)

Chronic active Epstein-Barr virus infection (CAEBV) represents a new subtype of lymphoproliferative disorders characterized by high morbidity and mortality rates and often leads to malignant transformation of infected cells. Efficient therapeutic strategies are presently unavailable; therefore, the development of therapies to prevent CAEBV-mediated transformation and disease progression is crucial. Here, we used microarray analysis and luciferase reporter assays to reveal the potential role of activated nuclear factor kappa B (NF-κB) in T cell type of-CAEBV infection. Using a series of cellular and molecular experiments, we demonstrated that dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, can selectively induce apoptosis in SNT-16 cells infected with CAEBV. Mechanistic studies suggested that DHMEQ induces SNT-16 cell apoptosis through NF-κB inhibition coupled with oxidative stress generation. Thus, activated NF-κB could be a new target for CAEBV therapeutics. Owing to its selective targeting ability, DHMEQ may be a candidate for a novel therapeutic regimen to control the progression of CAEBV infections.

Oxidative Stress
Chronic active Epstein-Barr Virus Infection
Back to top